IRB USE ONLY						
HSRP #:						
Date Rece	ived:					

Human Subjects Research Protocol Exempt, Expedited, or Full Board Review



Complete this form if "research" will be conducted.

Do not complete this form for:

- 1. non-research activities; or
- 2. to fulfill NVC coursework only without a research activity or element.

By signing this Human Subjects Research Protocol for Exempt, Expedited, or Full Board Review (HSRP), all Principal Investigators (PIs), co-PIs, and personnel (collectively, "Researchers") certify the following:

- 1. CITI Training "Social & Behavioral Research Basic/Refresher" course has been completed and is current for any research activity regardless of source of funding or whether unfunded (expires after three years);
- 2. CITI Training "Responsible Conduct of Research Course" has been completed in addition to the "Basic/Refresher" and is current only if the source of funding is the National Institutes of Health (NIH) or the National Science Foundation (NSF) (expires after three vears);
- 3. Have read and understood the responsibilities set forth in NVC Rule 15.99.01.C1.01;
- 4. If the HSRP is submitted for a doctoral dissertation, have coordinated with the Institutional Review Board (IRB) to meet its requirements:
- 5. Have read and reviewed this HSRP; any applicable supporting documentation or third-party approval has been obtained from the appropriate authority and has been included as an attachment to the HSRP (e.g., recruitment script, informed consent, parental consent, child assent, school permission, facility use permission, grant/proposal, Translator Certification, Interpreter Certification, etc); have signed the HSRP electronically;
- 6. Will immediately report any adverse event to the Institutional Review Board (IRB)
- 7. Have submitted the HSRP a minimum of thirty (30) days in advance of the anticipated start date (additional time is required for review at full board); will communicate whether there is a firm start date or other deadline associated with the HSRP; and
- 8. Will submit a Completion Report at the conclusion of research under this HSRP.

After completing the foregoing, submit the HSRP with supporting documentation via email to the IRB Mailbox: pnair2@alamo.edu & nvc-ir@alamo.edu

For questions, email:

pnair2@alamo.edu & nvc-ir@alamo.edu

Researchers											
	Name			nail /C email))		Co	llege	Category		egory her)
PI											
Co-PI (1)											
Co-PI (2)											
Co-PI (3)											
Co-PI (4)											
Co-PI (5)											
Overvie	w										
A. Researc	ch Classification:					Other:					
ORC and/or t	he IRB will ultimately be	responsible for makir	ng the Researd	ch Classif	ication c	and Level of	Review	. For guidance, se	e content at the end of the HSR	P.	
B. Anticipa	ated Level of Review	v:									
C. Externa	lly funded:		Awar	d Start	Date:		Maestro #:				
D. Title:											
E. Anticipa	ated Start Date:				F. F	Estimated	Com	pletion Date:			
Purpose	and Objective										
A. Describ	pe the purpose of th	e research <u>in la</u>	yman's tei	rms.							
B. Describ	pe the objective(s) a	nd/or research	questions	<u>in layn</u>	nan's i	terms.					
Particip	ants; Recruitmo	ent									
Participa	nnts										
	whether any of the			l be sp e	<u>ecifica</u>	lly targe	ted fo	or inclusion in	the research. Each cateş	gory m	ust be
	the age of 18 (<u>able</u> to			Yes 🗌	No [Prisoner	s (adu	lts or minors)		Yes	No 🗌
Minors und	er the age of 18	-		Yes	No [Persons minors)	whose	e first language	is <u>not</u> English (adults or	Yes	No
Persons with mental disabilities (adults or minors)				Yes	No [enrol	led in a researc	her's course (adults or	Yes	No 🗌
Persons with economical disadvantages (adults or minors)			Yes	No [Employe	es un	der the direct su	upervision of a researcher	Yes	No 🗌	
Persons with educational disadvantages (adults or minors)			Yes	No [-			ysical or mental)	Yes	No 🗌	
Persons with AIDS or HIV (adults or minors)			Yes	No [oopulations depending on arch (describe in " B ")	Yes	No 🔲	

Pregnant women, fetuses, and/or neonates Note: Research including this vulnerable population is <i>generally</i> health care/ medical studies specifically targeting research of pregnant women, fetuses, and/or neonates. Pregnant women can be included in research if all inclusion criteria is met and a specific exclusion is not part of the project design. Select No," unless the research specifically involves the inclusion of pregnant women, fetuses, and/or neonates.	Yes No						
B. Describe the criteria to determine who is included or <i>characteristics, learning characteristics, professional criteria, etc</i>).	r excluded i	n th	final participant _l	oopulation (e.g., mir	nimum age, grade i	range, pl	hysical
C. Target number of participants (use a minimum target if a s	specific taraet i	is not	appropriate for the res	earch desian).			
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
D. Non-NVC Participants or Facility Complete this section only if the research will be conduct site (non-NVC).	cted at a thi	rd-p	arty facility <u>or</u> par	ticipants will be re	ecruited from a	a third-	-party
Provide the non-NVC location or non-NVC participants	to be recrui	ited	1ere (include any pern	าission as an attachme	nt).		
Recruitment							
E(1). Method. Describe methods that will be used to id	entify the p	oter	tial participants.				
E(2). Materials. Describe how potential participants w they will be distributed (i.e., who, what, when, where, and how).		ited	what materials wi	ll be used (include a	s an attachment),	and ho)W
E(3). Incentives. If applicable, provide the amount, typ	e, and time	of d	stribution of any p	oayment/incentiv	e to participan	ts.	
Identification of Participants; Data Collection a	nd Storage	e; E	ղսipment; Reco	rds Retention a	and Destruct	ion	
A. Identification of Participants. Indicate whether the or whether the data will be collected anonymously.	data collect	ted 1	nay contain indivio	lual identifiers (n	eed for "confid	lentiali	ty"),
Anonymous							
B. Data Collection. Describe the method(s) or procedu frequency, duration, location, etc). The use of audio or video reresearch.							g party,

C. Equipment. Describe any equipment to be used (e.g., audio, visual), ownership (e.g., NVC, personal), and methods of storage (e.g., password, location).									
	D. Data Storage. Describe how the data collected will be stored, location(s), how the confidentiality of individually identifiable information will be maintained (if applicable), and who will have access. (For audio and video recordings, address recordings and transcripts).								
	Records Retention and Destruction. For data collected, describe ign and/or future research), destruction mechanism, and responsible pa								
Ris	sk to Participants; Mechanism of Protection; Outsid	e Assistance							
A. F	Risk to Participants. Indicate the level of risk to participants.								
No 1	risk		Yes 🗌	No 🗌					
Defi are 1	nimal risk nition: the probability and magnitude of harm or discomfort anticipated i not greater in and of themselves than those ordinarily encountered in dai performance of routine physical or psychological examinations or tests.		Yes 🗌	No 🗌					
Gre	ater than minimal risk		Yes 🗌	No 🗌					
("Ri	Mechanism of Protection. Describe every potential risk to huma isk"), and indicate the method or procedure to be used to mitigate chological, social, legal, and economic risks (e.g., breach of confidentiality)	the potential ri	sk ("Prote	ction Mec	hanism"). Consider physical,				
	Risk		Prot	ection M	echanism				
1.									
2.									
3.									
4.									
5.					_				
	Outside Assistance. If applicable, describe any outside assistance w it will be provided (e.g., medical care, counseling, etc).	available to pai	rticipants (to mitigat	e the Risks stated above and				

Benefits to Participants; Benefits to Society	y						
A. Benefits to Participants. If applicable, describe the <i>(exclude payments/incentives)</i> . If there are no benefits, then	_		its to participants as a result of taking part in the researc	h			
B. Benefits to Society. Describe the potential benefits research.	to socie	ety or co	ntribution to generalizable knowledge as a result of the				
Waiver of Informed Consent; Waiver of Sig	ned In	forme	d Consent; Informed Consent Process				
A(1). Is a <u>waiver or alteration</u> of informed consent requested? (i.e., entire process is waived, or basic element(s) are altered) See Criteria for Waiver of Informed Consent at the end of the HSRP for guidance. If <u>"yes,"</u> go to C.	Yes 🗌	No 🗌	A(2). If "no," is a waiver of documentation of informed consent requested? (i.e., informed consent will be obtained without participants' signatures) See Criteria for Waiver of Documentation of Informed Consent at the end of the HSRP for guidance. If "yes," go to C.				
If <u>"no,</u> " go to A(2).			If <u>"no,"</u> go to B.				
B. Informed Consent Process. If "no" to both A(1) and A(2), describe below step-by-step how informed consent will be obtained. If the "short form" will be used, describe below (See Informed Consent Documentation at the end of the HSRP forguidance). Note: 1) Participants must be given time to review the informed consent and supporting documents and ask questions. 2) For minor participants, researchers must obtain both parental informed consent and a separate child assent written at an appropriate reading level. 3) For participants whose first language is not English, informed consent may be required in English and non-English. In addition, submission of a Translator Certification or Interpreter Certification form may be required. 4) For research conducted in conjunction with CCISD, follow those requirements, as applicable. ORC and the IRB cannot advise on CCISD requirements.							
why a waiver or alteration of informed consent and/o	o <u>r</u> a waiv s of the r	er of do	med Consent. If <u>"yes"</u> to either A(1) or A(2), describe be cumentation of informed consent is requested and how the secondary for Waiver of Informed Consent or Criteria for Waiver of				

Resear	cher Qualifications							
A. Describe qualifications or attach CVs/resumes for <u>all personnel listed</u> on the HSRP.								
Resear	cher Signatures							
set for (s) cer	ning this HSRP, the Researcher(s) certifies that he/she has re th in the section entitled "Instructions and Researcher Certif tifies that he/she will abide by any and all applicable federal ements from the Institutional Review Board (IRB).	fications" in relation to the research. In a	addition, the Researcher					
	Name	Conflict of Interest (select one)	Date					
PI								
	Signature:							
Co-PI (1)								
	Signature:							
Co-PI (2)								
	Signature:							
Co-PI (3)								
	Signature:							
Co-PI (4)								
	Signature:							
Co-PI (5)								
	Signature:							

Determination of Level of Review

Studies involving audiotaping and/or videotaping do not qualify for exempt review and will be reviewed at the level of expedited or full board.

Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.

Additional protections for participants may apply to research involving: pregnant women, human fetuses, and neonates; prisoners; children; and/or other vulnerable populations.

Exempt Review

- (1) Research conducted in established or commonly accepted educational settings, involving normal education practices, such as (i.) research on regular and special education instructional strategies, or (ii.) research on the effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods.
- 2) Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures or observation of public behavior, unless (i.) information obtained is recorded in such a manner that human subjects can be identified, directly or through identifiers linked to the subjects; and (ii.) any disclosure of human subjects' responses outside the research could reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, or reputation.
- 3) Research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation of public behavior that is not exempt under the previous paragraph, if (i.) the human subjects are elected or appointed public officials or candidates for public office; or (ii.) federal statute(s) require(s) without exception that the confidentiality of the personally identifiable information will be maintained throughout the research and thereafter.
- 4) Research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects.
- 5) Research and demonstration projects that are conducted by or subject to the approval of federal department or agency heads, and that are designed to study, evaluate, or otherwise examine (i.) public benefit or service programs (ii.) procedures for obtaining benefits or services under these programs (iii.) possible changes in or alternatives to those programs or procedures; or (iv.) possible changes in methods or levels of payment for benefits or services under those programs.
- 6) Taste and food quality evaluation and consumer acceptance studies (i.) if wholesome foods without additives are consumed or (ii.) if a food is consumed that contains a food ingredient at or below the level and for a use found to be safe, or agricultural chemical or environmental contaminant at or below the level found to be safe, by the Food and Drug Administration or approved by the Environmental Protection Agency or the Food Safety and Inspection Service of the U.S. Department of Agriculture.

Expedited Review

- (1) Clinical studies of drugs and medical devices only when condition (a) or (b) is met.
 - a. Research on drugs for which an investigational new drug application (21 CFR Part 312) is not required. (Note: Research on marketed drugs that significantly increases the risks or decreases the acceptability of the risks associated with the use of the product is not eligible for expedited review).
 - b. Research on medical devices for which (i) an investigational device exemption application (21 CFR Part 812) is not required; or (ii) the medical device is cleared/approved for marketing and the medical device is being used in accordance with its cleared/approved labeling.
- (2) Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows:
 - a. from healthy, nonpregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an 8 week period and collection may not occur more frequently than 2 times per week; or
 - b. from other adults and children, considering the age, weight, and health of the subjects, the collection amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection may not occur more frequently than 2 times per week.
- (3) Prospective collection of biological specimens for research purposes by noninvasive means.
 - Examples: (a) hair and nail clippings in a nondisfiguring manner; (b) deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction; (c) permanent teeth if routine patient care indicates a need for extraction; (d) excreta and external secretions (including sweat); (e) uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gumbase or wax or by applying a dilute citric solution to the tongue; (f) placenta removed at delivery; (g) amniotic fluid obtained at the time of rupture of the membrane prior to or during labor; (h) supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques; (i) mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings; (j) sputum collected after saline mist nebulization.
- (4) Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications).
 - Examples: (a) physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject's privacy; (b) weighing or testing sensory acuity; (c) magnetic resonance imaging; (d) electrocardiography, electroencephalography, thermography, detection of naturally occurring radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, doppler blood flow, and echocardiography; (e) moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate given the age, weight, and health of the individual.
- (5) Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected solely for nonresearch

purposes (such as medical treatment or diagnosis).

- (6) Collection of data from voice, video, digital, or image recordings made for research purposes.
- (7) Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies. (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b)(2) and (b)(3). This listing refers only to research that is not exempt).
- (8) Continuing review of research previously approved by the convened IRB as follows:
 - a. where (i) the research is permanently closed to the enrollment of new subjects; (ii) all subjects have completed all research-related interventions; and (iii) the research remains active only for long-term follow-up of subjects; or
 - b. where no subjects have been enrolled and no additional risks have been identified; or
 - c. where the remaining research activities are limited to data analysis.
- (9) Continuing review of research, not conducted under an investigational new drug application or investigational device exemption where categories two (2) through eight (8) do not apply but the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been
- (10) identified.

Criteria for Waiver of Informed Consent

- (c) An IRB may approve a consent procedure which does not include, or which alters, some or all of the elements of informed consent set forth above, or waive the requirement to obtain informed consent provided the IRB finds and documents that:
 - (1) The research or demonstration project is to be conducted by or subject to the approval of state or local government officials and is designed to study, evaluate, or otherwise examine: (i) public benefit or service programs; (ii) procedures for obtaining benefits or services under those programs; (iii) possible changes in or alternatives to those programs or procedures; or (iv) possible changes in methods or levels of payment for benefits or services under those programs; and
 - (d) The research could not practicably be carried out without the waiver or alteration. An IRB may approve a consent procedure which does not include, or which alters, some or all of the elements of informed consent set forth above, or waive the requirement to obtain informed consent provided the IRB finds and documents that:
 - (1) The research involves no more than minimal risk to the subjects;
 - (2) The waiver or alteration will not adversely affect the rights and welfare of the subjects;
 - (3) The research could not practicably be carried out without the waiver or alteration; and
 - (4) Whenever appropriate, the subjects will be provided with additional pertinent information after participation.

Criteria for Waiver of Documentation of Informed Consent

- (c) An IRB may waive the requirement for the investigator to obtain a signed consent form for some or all subjects if it finds either:
 - (1) That the only record linking the subject and the research would be the consent document and the principal risk would be potential harm resulting from a breach of confidentiality. Each subject will be asked whether the subject wants documentation linking the subject with the research, and the subject's wishes will govern; or
 - (2) That the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of the research context.

In cases in which the documentation requirement is waived, the IRB may require the investigator to provide subjects with a written statement regarding the research.

Informed Consent Documentation

- (a) Except as provided in paragraph (c) of this section, informed consent shall be documented by the use of a written consent form approved by the IRB and signed by the subject or the subject's legally authorized representative. A copy shall be given to the person signing the form.
- (b) Except as provided in paragraph (c) of this section, the consent form may be either of the following:
- (1) A written consent document that embodies the elements of informed consent required by §46.116. This form may be read to the subject or the subject's legally authorized representative, but in any event, the investigator shall give either the subject or the representative adequate opportunity to read it before it is signed; or
- (2) A short form written consent document stating that the elements of informed consent required by §46.116 have been presented orally to the subject or the subject's legally authorized representative. When this method is used, there shall be a witness to the oral presentation. Also, the IRB shall approve a written summary of what is to be said to the subject or the representative. Only the short form itself is to be signed by the subject or the representative. However, the witness shall sign both the short form and a copy of the summary, and the person actually obtaining consent shall sign a copy of the summary. A copy of the summary shall be given to the subject or the representative, in addition to a copy of the short form.